Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01, Zacks reports. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. The business had revenue of $1.57 million during the quarter, compared to the consensus estimate of $2.20 million.
Arbutus Biopharma Price Performance
Shares of Arbutus Biopharma stock traded up $0.04 on Tuesday, reaching $3.53. The company had a trading volume of 556,162 shares, compared to its average volume of 1,062,360. The firm's 50-day moving average price is $3.34 and its two-hundred day moving average price is $3.55. Arbutus Biopharma has a 1 year low of $2.30 and a 1 year high of $4.73. The firm has a market cap of $667.96 million, a price-to-earnings ratio of -8.24 and a beta of 1.93.
Analysts Set New Price Targets
A number of brokerages recently commented on ABUS. HC Wainwright reissued a "buy" rating and set a $5.00 price target on shares of Arbutus Biopharma in a research note on Tuesday, January 21st. Chardan Capital reissued a "buy" rating and issued a $5.00 target price on shares of Arbutus Biopharma in a report on Friday. Finally, StockNews.com upgraded shares of Arbutus Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $5.50.
View Our Latest Stock Report on ABUS
About Arbutus Biopharma
(
Get Free Report)
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.
See Also
Before you consider Arbutus Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arbutus Biopharma wasn't on the list.
While Arbutus Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
